The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …

An obstacle to cancer immunotherapy has been that the affinity of T-cell receptors (TCRs) for
antigens expressed in tumors is generally low. We initiated clinical testing of engineered T …

T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a
minority of patients with cancer. In the majority of these individuals, however, there is a …

Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …

The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been
attributed to supraphysiological signaling through CARs. Second-and later-generation …

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

Single and dual amino acid substitution variants were generated in the TCR CDRs of three
TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR …

Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …